<--- Back to Details
First PageDocument Content
Bladder cancer / Transitional cell carcinoma / Bacillus Calmette-Guérin / Carcinoma in situ / Immunotherapy / Urothelium / Mohamed Ghonim / Medicine / Oncology / Carcinoma
Date: 2014-06-17 14:15:59
Bladder cancer
Transitional cell carcinoma
Bacillus Calmette-Guérin
Carcinoma in situ
Immunotherapy
Urothelium
Mohamed Ghonim
Medicine
Oncology
Carcinoma

Microsoft Word - MCC11032.03001_301_interim _EAU2011_.doc

Add to Reading List

Source URL: www.bioniche.com

Download Document from Source Website

File Size: 280,29 KB

Share Document on Facebook

Similar Documents

# 3083 AGI-134, a fully synthetic α-Gal-based cancer immunotherapy that shows synergy with anti-PD-1 and favorable pre-clinical pharmacokinetic and toxicity profiles Sascha A. Kristian 1,*,#, Stephen M. Shaw 1,*, Kim Wi

DocID: 1vdls - View Document

Microsoft Word - ST64 Cancer Immunotherapy v1.0.docx

DocID: 1uTyz - View Document

April 18, 2018 Torii Pharmaceutical Co., Ltd. Price Listing on the NHI Reimbursement List and Launch of “CEDARCURE® Japanese Cedar Pollen Sublingual Tablets”, an Allergen Immunotherapy Tablet for Japanese Cedar Poll

DocID: 1uM8x - View Document

第42回 日本免疫学会学術集会 クリニカルセミナー 2 Sublingual immunotherapy for Japanese cedar pollinosis

DocID: 1untY - View Document

President of ORPHEUS Robert Adam Harris Professor in Immunotherapy in Neuroinflammation Karolinska Institutet Personal details:

DocID: 1u6T9 - View Document